VRNA

Ensifentrine (Inhaled)

Chronic obstructive pulmonary disease (COPD)

Stage (next event)

Expected Date

Phase 2 (Data)

Catalyst Info & Data Links

TITLE: Ensifentrine (Nebulized) in COPD - Phase 3 Data

  • ClinicalTrial.gov (NCT04091360): A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease


WHAT IS THE CATALYST EVENT?

  • Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”). This dual inhibition enables it to combine both bronchodilator and anti-inflammatory effects in one compound. Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), which is beneficial in reducing mucous viscosity and improving mucociliary clearance. Ensifentrine’s mechanism of action has the potential to alleviate respiratory symptoms such as breathlessness and cough and work against inflammation associated with COPD or inflammation triggered by viruses.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon